1
|
Tyagi IS, Tsui HYC, Chen S, Li X, Mat WK, Khan MA, Choy LB, Chan KYA, Chan TMD, Ng CPS, Ng HK, Poon WS, Xue H. Non-mitotic proliferation of malignant cancer cells revealed through live-cell imaging of primary and cell-line cultures. Cell Div 2024; 19:3. [PMID: 38341593 DOI: 10.1186/s13008-024-00109-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Accepted: 01/15/2024] [Indexed: 02/12/2024] Open
Abstract
INTRODUCTION Anti-mitosis has been a key strategy of anti-cancer therapies, targeting at a fundamental property of cancer cells, their non-controllable proliferation due to overactive mitotic divisions. For improved anti-cancer therapies, it is important to find out whether cancer cells can proliferate independent of mitosis and become resistant to anti-mitotic agents. RESULTS In this study, live-cell imaging was applied to both primary-cultures of tumor cells, and immortalized cancer cell lines, to detect aberrant proliferations. Cells isolated from various malignant tumors, such as Grade-III hemangiopericytoma, atypical meningioma, and metastatic brain tumor exhibit distinct cellular behaviors, including amoeboid sequestration, tailing, tunneling, nucleic DNA leakage, as well as prokaryote-like division such as binary fission and budding-shedding, which are collectively referred to and reported as 'non-mitotic proliferation' in this study. In contrast, benign tumors including Grade-I hemangiopericytoma and meningioma were not obvious in such behaviors. Moreover, when cultured in medium free of any anti-cancer drugs, cells from a recurrent Grade-III hemangiopericytoma that had been subjected to pre-operation adjuvant chemotherapy gradually shifted from non-mitotic proliferation to abnormal mitosis in the form of daughter number variation (DNV) and endomitosis, and eventually regular mitosis. Similarly, when treated with the anti-cancer drugs Epirubicin or Cisplatin, the cancer cell lines HeLa and A549 showed a shift from regular mitosis to abnormal mitosis, and further to non-mitosis as the dominant mode of proliferation with increasing drug concentrations. Upon removal of the drugs, the cells reversed back to regular mitosis with only minor occurrences of abnormal mitosis, accompanied by increased expression of the stem cell markers ALDH1, Sox, Oct4 and Nanog. CONCLUSIONS The present study revealed that various types of malignant, but not benign, cancer cells exhibited cellular behaviors indicative of non-mitotic proliferation such as binary fission, which was typical of prokaryotic cell division, suggesting cell level atavism. Moreover, reversible transitions through the three modes of proliferation, i.e., mitosis, abnormal mitosis and non-mitosis, were observed when anticancer drug concentrations were grossly increased inducing non-mitosis or decreased favoring mitosis. Potential clinical significance of non-mitotic proliferation in cancer drug resistance and recurrence, and its relationship with cancer stem cells are worthy of further studies.
Collapse
Affiliation(s)
- Iram Shazia Tyagi
- Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China
| | - Ho Yin Calvin Tsui
- Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China
| | - Si Chen
- Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China
| | - Xinyi Li
- Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China
| | - Wai-Kin Mat
- Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China
| | - Muhammad A Khan
- Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China
| | - Lucas Brendan Choy
- Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China
| | - Ka-Yin Aden Chan
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China
| | - Tat-Ming Danny Chan
- Division of Neurosurgery & CUHK Otto Wong Brain Tumour Centre, Department of Surgery, The Chinese University of Hong Kong (CUHK), Hong Kong, Hong Kong SAR, China
| | - Chi-Ping Stephanie Ng
- Division of Neurosurgery & CUHK Otto Wong Brain Tumour Centre, Department of Surgery, The Chinese University of Hong Kong (CUHK), Hong Kong, Hong Kong SAR, China
| | - Ho-Keung Ng
- Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China
| | - Wai Sang Poon
- Division of Neurosurgery & CUHK Otto Wong Brain Tumour Centre, Department of Surgery, The Chinese University of Hong Kong (CUHK), Hong Kong, Hong Kong SAR, China.
- Department of Neurosurgery, Neuro-Medical Centre, University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053, Guangdong, China.
| | - Hong Xue
- Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong SAR, China.
- Center for Cancer Genomics, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
- Guangzhou HKUST Fok Ying Tung Research Institute, Science and Technology Building, Nansha Information Technology Park, Nansha, 511458, Guangzhou, China.
| |
Collapse
|
2
|
Zhang L, Chen F, Xu L, Li N, Zhuo Q, Guo Y, Wang X, Wen M, Zhao Z, Li M. Comprehensive review of solid tumor bone marrow metastasis. Crit Rev Oncol Hematol 2024; 194:104248. [PMID: 38145832 DOI: 10.1016/j.critrevonc.2023.104248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2023] [Revised: 12/03/2023] [Accepted: 12/20/2023] [Indexed: 12/27/2023] Open
Abstract
Bone marrow metastasis (BMM) of solid tumors refers to a group of diseases that originate from non-hematopoietic malignant tumor cells invading the bone marrow (BM) through complex metastatic patterns. If BMM identification is delayed, the disease will rapidly develop into disseminated carcinogenesis of the BM, which manifests as a series of hematological disorders and microangiopathic hemolytic anemia, leading to serious life-threatening conditions. Although the study of solid tumor BMM is receiving increasing attention, study remains limited, and most descriptions are derived from case reports. Currently, clinicians have insufficient understanding of BMM, and BMM occurrence is often not recognized early or treated effectively, resulting in high mortality rates. In this article, we review the epidemiology, molecular mechanisms, clinical diagnosis, treatment, and prognosis of solid tumor BMM.
Collapse
Affiliation(s)
- Lanxin Zhang
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
| | - Fengxi Chen
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
| | - Lingzhi Xu
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
| | - Ning Li
- Dalian Medical University, Dalian, Liaoning, China
| | - Qiping Zhuo
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
| | - Yijin Guo
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
| | - Xueqing Wang
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
| | - Meijie Wen
- Department of Anesthesia & Operating Theater, China-Japan Friendship Hospital, Beijing, China
| | - Zuowei Zhao
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China; Department of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
| | - Man Li
- Department of Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
| |
Collapse
|